BACKGROUND: We used doxorubicin-based chemotherapy as a clinical model of oxidative assault in humans. METHODS: The study recruited newly diagnosed breast cancer patients (n = 23). Urine samples were collected immediately before (T0) and at 1 hour (T1) and 24 hours (T24) after i.v. administration of treatment. Measurements included allantoin and the isoprostanes iPF(2alpha)-III, iPF(2alpha)-VI, and 8,12-iso-iPF(2alpha)-VI along with the prostaglandin 2,3-dinor-iPF(2alpha)-III, a metabolite of iPF(2alpha)-III. All biomarkers were quantified using liquid chromatography-tandem mass spectrometry. RESULTS: In all subjects, the levels of the biomarkers increased at T1: allantoin by 22% (P = 0.06), iPF(2alpha)-III by 62% (P < 0.05), iPF(2alpha)-VI by 41% (P < 0.05), 8,12-iso-iPF(2alpha)-VI by 58% (P < 0.05), and 2,3-dinor-iPF(2alpha)-III by 52% (P < 0.05). At T24, the F2-isoprostanes returned to their baseline levels; the levels of allantoin continued to increase, although the T24-T0 difference was not statistically significant. CONCLUSIONS: These results indicate that urinary F2-isoprostanes are valid biomarkers and allantoin is a promising biomarker of oxidative status in humans. IMPACT: The levels of biomarkers change quickly in response to oxidative assault and can be used to monitor oxidative status in humans in response to treatments related either to generation of free radicals (chemotherapy and radiation therapy) or to antioxidants (inborn metabolic diseases and Down syndrome). Copyright 2010 AACR.
BACKGROUND: We used doxorubicin-based chemotherapy as a clinical model of oxidative assault in humans. METHODS: The study recruited newly diagnosed breast cancerpatients (n = 23). Urine samples were collected immediately before (T0) and at 1 hour (T1) and 24 hours (T24) after i.v. administration of treatment. Measurements included allantoin and the isoprostanes iPF(2alpha)-III, iPF(2alpha)-VI, and 8,12-iso-iPF(2alpha)-VI along with the prostaglandin 2,3-dinor-iPF(2alpha)-III, a metabolite of iPF(2alpha)-III. All biomarkers were quantified using liquid chromatography-tandem mass spectrometry. RESULTS: In all subjects, the levels of the biomarkers increased at T1: allantoin by 22% (P = 0.06), iPF(2alpha)-III by 62% (P < 0.05), iPF(2alpha)-VI by 41% (P < 0.05), 8,12-iso-iPF(2alpha)-VI by 58% (P < 0.05), and 2,3-dinor-iPF(2alpha)-III by 52% (P < 0.05). At T24, the F2-isoprostanes returned to their baseline levels; the levels of allantoin continued to increase, although the T24-T0 difference was not statistically significant. CONCLUSIONS: These results indicate that urinary F2-isoprostanes are valid biomarkers and allantoin is a promising biomarker of oxidative status in humans. IMPACT: The levels of biomarkers change quickly in response to oxidative assault and can be used to monitor oxidative status in humans in response to treatments related either to generation of free radicals (chemotherapy and radiation therapy) or to antioxidants (inborn metabolic diseases and Down syndrome). Copyright 2010 AACR.
Authors: M B Kadiiska; B C Gladen; D D Baird; D Germolec; L B Graham; C E Parker; A Nyska; J T Wachsman; B N Ames; S Basu; N Brot; G A Fitzgerald; R A Floyd; M George; J W Heinecke; G E Hatch; K Hensley; J A Lawson; L J Marnett; J D Morrow; D M Murray; J Plastaras; L J Roberts; J Rokach; M K Shigenaga; R S Sohal; J Sun; R R Tice; D H Van Thiel; D Wellner; P B Walter; K B Tomer; R P Mason; J C Barrett Journal: Free Radic Biol Med Date: 2005-03-15 Impact factor: 7.376
Authors: M B Kadiiska; B C Gladen; D D Baird; L B Graham; C E Parker; B N Ames; S Basu; G A Fitzgerald; J A Lawson; L J Marnett; J D Morrow; D M Murray; J Plastaras; L J Roberts; J Rokach; M K Shigenaga; J Sun; P B Walter; K B Tomer; J C Barrett; R P Mason Journal: Free Radic Biol Med Date: 2005-03-15 Impact factor: 7.376
Authors: M B Kadiiska; B C Gladen; D D Baird; A E Dikalova; R S Sohal; G E Hatch; D P Jones; R P Mason; J C Barrett Journal: Free Radic Biol Med Date: 2000-03-15 Impact factor: 7.376
Authors: Dora Il'yasova; Frances Wang; Ivan Spasojevic; Karel Base; Ralph B D'Agostino; Lynne E Wagenknecht Journal: Obesity (Silver Spring) Date: 2011-09-29 Impact factor: 5.002
Authors: Ijeoma Esiaba; Danilyn M Angeles; Megan S Holden; John B C Tan; Yayesh Asmerom; Gerald Gollin; Danilo S Boskovic Journal: Transl Stroke Res Date: 2015-05-22 Impact factor: 6.829
Authors: Leanne M Redman; Steven R Smith; Jeffrey H Burton; Corby K Martin; Dora Il'yasova; Eric Ravussin Journal: Cell Metab Date: 2018-03-22 Impact factor: 27.287
Authors: Adviye A Tolun; Peter M Scarbrough; Haoyue Zhang; Jane-Ann McKillop; Frances Wang; Priya S Kishnani; David S Millington; Sarah P Young; Dora Il'yasova Journal: Ann Epidemiol Date: 2012-10-11 Impact factor: 3.797
Authors: Jeevan K Prasain; Alireza Arabshahi; Pam R Taub; Scott Sweeney; Ray Moore; J Daniel Sharer; Stephen Barnes Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2012-12-20 Impact factor: 3.205